The current reimbursement environment is characterised by rapidly changing payer markets and reference pricing systems. In response, we offer strategies to overcome these challenges that minimise potential delays in achieving reimbursement status and enhance meeting targeted budgets. IMS consultants plan approaches that highlight products’ significant benefits and apply their experiences, skills and resources to nominate the most appropriate comparator for submissions.
As Australia’s largest and most experienced reimbursement specialists, the IMS Pricing & Market Access team offers expert advice that provides commercial clients with the best opportunity to attain listing for reimbursement. Our team of highly experienced consultants, including a former PBAC member with over 6 years evaluation experience, provide competitive advantage in strategy development for reimbursement submissions.
Our consultants have prepared more than 300 applications for products seeking reimbursement through Australian government initiatives. By interrogating newly developed longitudinal databases, such as the IMS Reimbursement Database, we capture data that allows economic modelling of the Australian reimbursement system from 1992 to the present time. Analysis results are applied to predict PBS shifts and to quantify potential impact of new government policy on pharmaceutical sales and revenue. Our consultants maintain experience in all therapeutic areas including key markets - cardiovascular, oncology and central nervous system (CNS).